Journal of NeuroVirology

, Volume 12, Issue 5, pp 403–406

Valproic acid does not affect markers of human immunodeficiency virus disease progression

  • Beau M. Ances
  • Scott Letendre
  • Maria Buzzell
  • Jennifer Marquie-Beck
  • Deborah Lazaretto
  • Thomas D. Marcotte
  • Igor Grant
  • Ronald J. Ellis
  • HNRC Group
Short Communication

DOI: 10.1080/13550280600981695

Cite this article as:
Ances, B.M., Letendre, S., Buzzell, M. et al. Journal of NeuroVirology (2006) 12: 403. doi:10.1080/13550280600981695

Abstract

Valproic acid (VPA) reduces latent human immunodeficiency virus (HIV) reservoirs by activating resting CD4+ cells. This retrospective case-control study (n = 30) examined effects of VPA on markers of HIV progression. VPA was not associated with changes in cerebrospinal fluid viral loads (VL), plasma VL, or neuropsychological performance. VPA patients had a trend towards lower CD4+ cells (P = .08) at follow-up. Concurrent antiretrovirals did not alter these relationships. VPA does not induce viremia or promote disease progression and may be safe for clinical intervention.

Keywords

CD4+ cell HIV latent virus valproic acid viral load 

Copyright information

© Journal of NeuroVirology, Inc. 2006

Authors and Affiliations

  • Beau M. Ances
    • 1
    • 4
  • Scott Letendre
    • 2
  • Maria Buzzell
    • 1
  • Jennifer Marquie-Beck
    • 1
  • Deborah Lazaretto
    • 1
  • Thomas D. Marcotte
    • 3
  • Igor Grant
    • 3
  • Ronald J. Ellis
    • 1
  • HNRC Group
  1. 1.Department of NeurosciencesUniversity of CaliforniaSan DiegoUSA
  2. 2.Department of MedicineUniversity of CaliforniaSan DiegoUSA
  3. 3.Department of PsychiatryUniversity of CaliforniaSan DiegoUSA
  4. 4.HIV Neurobehavioral Research CenterSan DiegoUSA

Personalised recommendations